| [September 29, 2016] |
 |
Enanta Pharmaceuticals Presents Data on a Novel Non-Fusion Inhibitor of Respiratory Syncytial Virus (RSV) at the 10th Annual Respiratory Syncytial Virus Conference
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and
development-focused biotechnology company dedicated to creating small
molecule drugs for viral infections and liver diseases, today announced
that a poster presentation on one of the lead compounds in its RSV
program was presented today at the 10th Annual Respiratory
Syncytial Virus conference taking place September 28 through October 1,
in Patagonia, Argentina.
Data presented in a poster titled, EP-023938, A Novel Non-Fusion
Replication Inhibitor of Respiratory Syncytial Virus (RSV), M.H. J.
Rhodin, et al., demonstrated that EP-023938 is a potent inhibitor of
both RSV-A and RSV-B activity, maintaining antiviral activity
post-infection while presenting a high barrier to resistance. Further,
EP-023938 maintained antiviral potency across all clinical isolates
tested as well as virus that was resistant to fusion inhibitors. Given
this favorable preclinical profile, along with demonstrated synergy with
inhibitors of other mechanisms, Enanta plans to continue evaluation of
EP-023938 as a potential development candidate for RSV.
EP-023938 is a non-fusion inhibitor and one of several discovered by
Enanta for potential development for RSV. Enanta believes that its
approach differentiates its compounds from fusion inhibitors currently
in development for RSV because its non-fusion inhibitors directly target
the virus replication machinery and have demonstrated high barriers to
resistance against the virus in vitro. Additionally, non-fusion
inhibitors have the potential of being effective at later stages of
infection.
The abstract can be viewed at http://www.rsv16.org/.
About RSV
Respiratory syncytial virus (RSV) is a virus that
infects the lungs and represents a serious unmet medical need in infants
and children, as well as immune-compromised individuals and the elderly.
RSV s the most common cause of bronchiolitis (inflammation of the small
airways in the lung) and pneumonia in children under 1 year of age in
the United States. Each year, 75,000 to 125,000 children in this group
are hospitalized due to RSV infection. Children with compromised
(weakened) immune systems due to a medical condition or medical
treatment, adults with compromised immune systems and those 65 and older
are also at increased risk of severe disease. There is currently no
effective treatment available for treating RSV infection.
About Enanta
Enanta Pharmaceuticals is a research and
development-focused biotechnology company that uses its robust
chemistry-driven approach and drug discovery capabilities to create
small molecule drugs for viral infections and liver diseases. Enanta's
research and development efforts are currently focused on four disease
targets: Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), Non-alcoholic
Steatohepatitis (NASH) and Respiratory Syncytial Virus (RSV).
Enanta has discovered novel protease inhibitors and NS5A inhibitors that
are members of the direct-acting-antiviral (DAA) inhibitor classes
designed for use against the hepatitis C virus (HCV). Enanta's protease
inhibitors, developed through its collaboration with AbbVie, include
paritaprevir, which is contained in AbbVie's marketed DAA regimens for
HCV, and ABT-493, Enanta's second protease inhibitor, which AbbVie is
developing in Phase 3 studies in combination with ABT-530, AbbVie's NS5A
inhibitor. Enanta has also discovered a cyclophilin inhibitor, EDP-494,
a novel host-targeting mechanism for HCV, which is now in a clinical
proof of concept study in HCV patients, and EDP-305, a non-bile acid FXR
agonist for NASH, currently in Phase 1 clinical development. Please
visit www.enanta.com
for more information on our programs and pipeline.
Forward Looking Statements Disclaimer
This press release
contains forward-looking statements, including statements with respect
to the prospects for development of one of Enanta's lead compounds for
the treatment of RSV. Statements that are not historical facts are based
on management's current expectations, estimates, forecasts and
projections about Enanta's business and the industry in which it
operates and management's beliefs and assumptions. The statements
contained in this release are not guarantees of future performance and
involve certain risks, uncertainties and assumptions, which are
difficult to predict. Therefore, actual outcomes and results may differ
materially from what is expressed in such forward-looking statements.
Important factors and risks that may affect actual results include: the
development risks of early stage discovery efforts in disease areas such
as RSV that have no current therapeutic treatment; potential competition
from the development efforts of others in this disease area; Enanta's
lack of clinical development experience; Enanta's need to attract and
retain senior management and key scientific personnel; Enanta's need to
obtain and maintain patent protection for its product candidates and
avoid potential infringement of the intellectual property rights of
others; and other risk factors described or referred to in "Risk
Factors" in Enanta's most recent Form 10-K for the fiscal year ended
September 30, 2015 and other periodic reports filed more recently with
the Securities and Exchange Commission. Enanta cautions investors not to
place undue reliance on the forward-looking statements contained in this
release. These statements speak only as of the date of this release, and
Enanta undertakes no obligation to update or revise these statements,
except as may be required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160929006345/en/
[ Back To TMCnet.com's Homepage ]
|
